(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193979 A1

(51) International Patent Classification:
A61K 31/439 (2006.01) *A61K 31/498* (2006.01)
A61F 9/00 (2006.01) *A61K 47/26* (2006.01)
A61J 1/06 (2006.01) *A61K 47/38* (2006.01)
A61J 1/14 (2023.01) *A61P 27/06* (2006.01)
A61K 9/00 (2006.01) *A61P 27/10* (2006.01)

(21) International Application Number:
PCT/US2025/019824

(22) International Filing Date:
13 March 2025 (13.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

18/606,372	15 March 2024 (15.03.2024)	US
63/565,668	15 March 2024 (15.03.2024)	US
63/565,672	15 March 2024 (15.03.2024)	US
63/565,674	15 March 2024 (15.03.2024)	US
63/565,679	15 March 2024 (15.03.2024)	US
63/565,687	15 March 2024 (15.03.2024)	US
63/565,692	15 March 2024 (15.03.2024)	US
63/573,626	03 April 2024 (03.04.2024)	US
63/573,630	03 April 2024 (03.04.2024)	US
63/573,632	03 April 2024 (03.04.2024)	US
63/573,636	03 April 2024 (03.04.2024)	US
63/573,640	03 April 2024 (03.04.2024)	US
63/573,641	03 April 2024 (03.04.2024)	US
63/660,848	17 June 2024 (17.06.2024)	US
63/660,853	17 June 2024 (17.06.2024)	US
63/660,858	17 June 2024 (17.06.2024)	US
63/660,959	17 June 2024 (17.06.2024)	US
63/660,962	17 June 2024 (17.06.2024)	US
63/660,969	17 June 2024 (17.06.2024)	US
18/939,325	06 November 2024 (06.11.2024)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 18/606,372 (CIP)
Filed on 15 March 2024 (15.03.2024)
US 18/939,325 (CIP)
Filed on 06 November 2024 (06.11.2024)

(71) Applicant: **LENZ THERAPEUTICS OPERATIONS, INC.** [US/US]; 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, California 92075 (US).

(72) Inventor: **HORN, Gerald**; 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, California 92075 (US).

(54) Title: SYSTEMS AND COMPOSITIONS FOR USE IN TREATING PRESBYOPIA

(57) Abstract: The present disclosure provides aqueous compositions comprising aceclidine that are stable at room temperature for prolonged periods of time. The present disclosure also provides systems comprising a container, such as a single use container, and an ophthalmological composition, such as comprising aceclidine. Also provided are methods of using such systems, containers, and compositions, such as in the treatment of ocular disorders (e.g., presbyopia).




FIG. 12

WO 2025/193979 A1

[Continued on next page]

(74) **Agent: WILLIAMSON, David R.** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*